Alnylam Expands Asian Presence With RNAi License To Japan's GeneDesign

Alnylam Pharmaceuticals has granted Osaka, Japan-based GeneDesign a nonexclusive license to provide small interfering RNA research products and services using Alnylam's Kreutzer-Limmer patent estate, the companies announced Oct. 3

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Archive

More from Scrip